Big Pharma Sells Ineffective, Potentially Deadly Anti-Cancer Drugs

New Eastern Outlook
by Vladimir Platov

5603674513_4b491438d1_o_slideshowMedical experts are saying that the biggest flaw of Big Pharma today is a high percentage of ineffective products being sold without previous clinical trials. This is particularly true when anti-cancer medications are concerned. The sad fact is that Big Pharma prefers to invest in advertising and bribing officials instead of attempting to make their products truly effective. Today pharmaceutical manufacturing is handsomely funded by politicians and organized crime, since it’s has become one of the most efficient money laundering schemes that has already corrupted a large number of US and EU officials.

Biotech expert C. Glenn Begley, the former Vice-President and Global Head of Hematology and Oncology Research at Amgen – one of the largest cancer research centers in the US, is now a senior vice president in a private biotech company TetraLogic. In his article published in the Nature magazine back in March 2012, Glenn stated that a series of tests conducted under his supervision proved that out of 53 anti-cancer drugs that had been developed by “respected laboratories,” a total of 47 showed no noticeable improvements in patients’ health conditions (which amounts to 88%).

Unfortunately, this study was proven right by a number of research teams, that got similar results while running tests. In 2009, a group of researchers at Michigan State University reached a similar conclusion, just like Bayer‘s research team. At the same time certain researchers, like the famous Harvard Medical School prefer to falsifiy their studies to get a hefty grant of 15 million dollars from the Federal government.

Big Parma is all about PR campaigns and advertisement, while putting new potentially dangerous drugs on the market. For example, Glivec and Sutent, that are authorized for usage in Europe, are reducing the size of tumours by wiping out pericytes that prevent the growth of tumour-nourishing blood vessels. As a result, additional testings showed, these drugs force cancer to spread faster across a body, making it increasingly more deadly.

Canadian Professor at the Department of Pharmacology at Dalhousie University, George S. Robertson is also stressing the innefectivness of certain drugs that are being put on the market today.

Over the past two decades, the most promising drugs that should have allowed the people to fight cancer effectively were Gleevec and Herceptin. However, as it has been recently discovered, each of these medications initiated genetic mutations of cells, by turning a regular one into a malignant cell.

Scientists from Bayer had little luck with their studies as well. In 2011, in a paper “Believe it or not”, Bayer admitted that researchers couldn’t get the same results on clinical trial on stage two of their testings. The head of Target Discovery at Bayer Schering Pharma admitted that research teams couldn’t replicate the initial results of most of Bayer’s studies, no matter how hard they tried. Out of 47 potential new anti-cancer drugs less than one-quarter got behind stage two. The scandal that followed put an end to all of anti-cancer studies at Bayer altogether.

According to C. Glenn Begley, when the investigation Amgen Inc, consisting of approximately 100 scientists could not confirm the official results of clinical trials, they contacted the producers of these drugs. Some of them demanded that Amgen Inc should sign a non-disclosure agreement that should keep the facts from being published.

In pursuit of federal grants Big Pharma is falsifying researches, by paying for factless publications in scientific journals, which must open a direct path to the introduction of new drugs on the market, regardless of their potential danger. Unfortunatelly, the common people across the globe are to pay for this deceit, more often than not with their own lives.

Vladimir Platov, Middle East expert, exclusively for the online magazine “New Eastern Outlook”.

New Eastern Outlook